FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Introduction: FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of selective FLT3 inhibitors. Combination approaches with o...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Douglas D. Fang, Hengrui Zhu, Qiuqiong Tang, Guangfeng Wang, Ping Min, Qixin Wang, Na Li, Dajun Yang, Yifan Zhai
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2022-01-01
Цуврал:	Translational Oncology
Нөхцлүүд:	FLT3-ITD BCL-2 HQP1351 APG-2575 Acute myeloid leukemia
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S1936523321002369
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!